Evidence map›Paper›PMID 23009582›Full record

ArticleCancer biotherapy & radiopharmaceuticals2012

Comparison of cell-labeling methods with ¹²⁴I-FIAU and ⁶⁴Cu-PTSM for cell tracking using chronic myelogenous leukemia cells expressing HSV1-tk and firefly luciferase.

Jae-Jun Park, Tae-Sup Lee, Jin-Ju Son, Kwon-Soo Chun, In-Ho Song, Yong-Serk Park, Kwang-Il Kim, Yong-Jin Lee, Joo-Hyun Kang

Abstract read
In one paragraph

Article in Cancer biotherapy & radiopharmaceuticals, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 24 citations in OpenAlex.

  1. Stem cells therapy molecular tracking - the special focus on nuclear medicine.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Stem Cell Monitoring with a Direct or Indirect Labeling Method.Nuclear medicine and molecular imaging · 2016
    Review
  13. Article
  14. Article
  15. Article
  16. [(89)Zr]oxinate4 for long-term in vivo cell tracking by positron emission tomography.European journal of nuclear medicine and molecular imaging · 2015
    Article
  17. A kit formulation for the preparation of [Nuclear medicine and biology
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Jae-Jun ParkMolecular Imaging Research Center, Korea Institute of Radiological and Medical Sciences-KIRAMS, Seoul, Republic of Korea.
Tae-Sup Lee
Jin-Ju Son
Kwon-Soo Chun
In-Ho Song
Yong-Serk Park
Kwang-Il Kim
Yong-Jin Lee
Joo-Hyun Kang
Korea Institute of Radiological and Medical Sciences · KRYonsei University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cell-tracking methods with molecular-imaging modality can monitor the biodistribution of cells. In this study, the direct-labeling method with ⁶⁴Cu-pyruvaldehyde-bis(N4-methylthiosemicarbazone) (⁶⁴Cu-PTSM), indirect cell-labeling methods with herpes simplex virus type 1-thymidine kinase (HSV1-tk)-mediated ¹²⁴I-2'-fluoro-2'-deoxy-1-β-D-arabinofuranosyl-5-iodouracil (¹²⁴I-FIAU) were comparatively investigated in vitro and in vivo for tracking of human chronic myelogenous leukemia cells. K562-TL was established by retroviral transduction of the HSV1-tk and firefly luciferase gene in the K562 cell. K562-TL cells were labeled with ⁶⁴Cu-PTSM or ¹²⁴I-FIAU. Cell labeling efficiency, viability, and radiolabels retention were compared in vitro. The biodistribution of radiolabeled K562-TL cells with each radiolabel and small-animal positron emission tomography imaging were performed. Additionally, in vivo and ex vivo bioluminescence imaging (BLI) and tissue reverse transcriptase-polymerase chain reaction (RT-PCR) analysis were used for confirming those results. K562-TL cells were efficiently labeled with both radiolabels. The radiolabel retention (%) of ¹²⁴I-FIAU (95.2%±1.1%) was fourfold higher than ⁶⁴Cu-PTSM (23.6%±0.7%) at 24 hours postlabeling. Viability of radiolabeled cells was statistically nonsignificant between ¹²⁴I-FIAU and ⁶⁴Cu-PTSM. The radioactivity of each radiolabeled cells was predominantly accumulated in the lungs and liver at 2 hours. Both the radioactivity of ⁶⁴Cu-PTSM- and ¹²⁴I-FIAU-labeled cells was highly accumulated in the liver at 24 hours. However, the radioactivity of ¹²⁴I-FIAU-labeled cells was markedly decreased from the body at 24 hours. The K562-TL cells were dominantly localized in the lungs and liver, which also verified by BLI and RT-PCR analysis at 2 and 24 hours postinjection. The ⁶⁴Cu-PTSM-labeled cell-tracking method is more efficient than ¹²⁴I-FIAU-labeled cell tracking, because of markedly decrease of radioactivity and fast efflux of ¹²⁴I-FIAU in vivo. In spite of a high labeling yield and radiolabel retention of ¹²⁴I-FIAU in vitro, the in vivo cell-tracking method using ⁶⁴Cu-PTSM could be a useful method to evaluate the distribution and targeting of various cell types, especially, stem cells and immune cells.

Indexed as

AnimalsArabinofuranosyluracilCell TrackingCopper RadioisotopesFemaleGene Transfer TechniquesHerpesvirus 1, HumanHumansIodine RadioisotopesK562 CellsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLuciferases, FireflyMiceMice, Inbred BALB CMice, NudeOrganometallic CompoundsArabinofuranosyluracilcopper pyruvaldehyde bis(N(4)-methylthiosemicarbazone) complexCopper RadioisotopesfialuridineIodine RadioisotopesLuciferases, FireflyOrganometallic CompoundsRadiopharmaceuticalsThiosemicarbazonesThymidine Kinase

Identifiers

PMID23009582
PMCPMC3516418
OpenAlexW1974853849

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.